Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Tonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
